Pharma BD Deal Intelligence

Lyell Immunopharma, Inc. / Innovative Cellular Therapeutics Holdings Limited

2025 · Licensing/Option · Complete

Lyell Immunopharma entered an exclusive license agreement with Innovative Cellular Therapeutics for the development and commercialization of LYL273, a GCC-targeted CAR T-cell product candidate for metastatic colorectal cancer and other GCC-expressing cancers. Lyell received exclusive global rights outside mainland China, Hong Kong, Macau and Taiwan in exchange for a USD 40 million cash upfront payment and the issuance of 1.9 million shares of Lyell common stock.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals